Inhibition of c. difficile infections by indigestible oligosaccharides
CA 2217157 C · Owner: Garleb, Keith Allen · Inventors: Walton, Joseph Edward; Garleb, Keith Allen; Campbell, Shelia Martinson
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The primary etiology of antibiotic-associated diarrhea (also known as pseudomembranous colitis) has been recognized as Clostridium difficile. It is believed that the indigenous microflora of a healthy individual suppresses the normally present C. difficile. However when the indigenous microflora are , disrupted (e.g. during antibiotic treatment) overgrowth of C. difficile may occur causing diarrhea and colitis. Treatment of C. difficile with antibiotics has proven effective, but many times relapse occurs; and dehydration due to diarrhea is an exacerbating problem. It has been suggested that normalization of the microflora will inhibit C. difficile relapse. Indigestible …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 4, 1996 and granted July 30, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 4, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 4, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.